2025 Research
Conscience Announces Recipients of Inaugural Program to Foster Collaborative Drug Discovery and Development
TORONTO--(BUSINESS WIRE)--Conscience, a non-profit focused on accelerating drug discovery in areas of unmet medical need using open science and radical collaboration, is pleased to announce three recipients and projects have been approved for its Developing Medicines through Open Science (DMOS) program. The DMOS program is designed to foster collaborative drug discovery and development in areas often overlooked by the pharmaceutical industry, such as rare and orphan diseases and antimicrobial resistance. The inaugural round of this program is offering a total of $5M in funding and partnership opportunities to support significant advancements toward drug candidates. Project 1. Focus: Small Molecule PRMT6 Inhibitors for the Treatment of Spinal Bulbar Muscular Atrophy. To read the article, click here.
The University of Rochester announces the SBMA-Health Index, a rating scale for patient-related outcome measure for Kennedy's Disease. To view the rating scale, click here.
